Yesterday, Vigilant Biosciences introduced the world to its OncAlert Oral Cancer Risk Assessment System, the company’s revolutionary oral cancer screening and identification product. To top things off, it also announced $5 million in guaranteed purchases in a five-year exclusive distribution agreement in Korea with BL&H.

How does the system work, and what will the industry impact be? To get the answer, we interviewed Dr. John Comisi, Chief Dental Officer for Vigilant. Watch now

Source: APEX360